UnitedHealthcare Pharmacy Clinical Pharmacy Programs
|
|
|
- Arabella Griffith
- 5 years ago
- Views:
Transcription
1 UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P Program Step Therapy - Anticonvulsants Medication/Therapeutic Class Anticonvulsants Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal XR, Lamictal ODT, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Mysoline, Neurontin, Oxtellar XR*, Qudexy XR* (brand and authorized generic), Spritam*, Topamax, Trileptal, Trokendi XR*, Zonegran P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018 Effective Date 12/1/2018; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Mysoline, Neurontin, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the step 1 medication in the previous 6 months, the prescription will process automatically. The brand version of each generic step 1 medication will also qualify. Members currently on therapy will be grandfathered. 1
2 2. Coverage Criteria a : A. Depakote will be approved based on one of the following criteria: a. History of 2 week trial of divalproex sodium delayed release b. History of an inadequate response to divalproex sodium delayed-release 2. History of intolerance to generic divalproex sodium delayed-release formulations 3. Patient is receiving Depakote for the treatment of a seizure disorder B. Depakote ER will be approved based on one of the following criteria: a. History of 2 week trial of divalproex sodium ER b. History of an inadequate response to divalproex sodium ER 2. History of intolerance to generic divalproex sodium extended release formulations 3. Patient is receiving Depakote ER for the treatment of a seizure disorder C. Felbatol will be approved based on one of the following criteria: a. History of 2 week trial of felbamate 2
3 -ANDb. History of an inadequate response to felbamate 2. History of intolerance to generic felbamate formulations 3. Patient is receiving Felbatol for the treatment of a seizure disorder D. Keppra will be approved based on one of the following criteria: a. History of 2 week trial of levetiracetam b. History of an inadequate response to levetiracetam 2. History of intolerance to generic levetiracetam formulations 3. Patient is receiving Keppra for the treatment of a seizure disorder E. Keppra XR will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic levetiracetam (2) generic levetiracetam extended release b. History of an inadequate response to one of the following: (1) generic levetiracetam (2) generic levetiracetam extended release 3
4 2. History of intolerance to one of the following: (1) generic levetiracetam (2) generic levetiracetam extended release 3. Patient is receiving Keppra XR for the treatment of a seizure disorder F. Lamictal will be approved based on one of the following criteria: a. History of 2 week trial of lamotrigine b. History of an inadequate response to lamotrigine 2. History of intolerance to generic lamotrigine formulations 3. Patient is receiving Lamictal for the treatment of a seizure disorder G. Lamictal ODT will be approved based on one of the following criteria: a. History of 2 week trial of lamotrigine orally disintegrating tablet b. History of an inadequate response to lamotrigine orally disintegrating tablet 2. History of intolerance to lamotrigine orally disintegrating tablet 4
5 3. Patient is receiving Lamictal ODT for the treatment of a seizure disorder H. Lamictal XR will be approved based on one of the following criteria: a. History of 2 week trial of lamotrigine extended-release -ANDb. History of an inadequate response to lamotrigine extended-release 2. History of intolerance to generic lamotrigine extended-release formulations 3. Patient is receiving Lamictal XR for the treatment of a seizure disorder I. Lamotrigine extended-release will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic lamotrigine (2) Lamictal immediate release b. History of an inadequate response to one of the following: (1) generic lamotrigine (2) Lamictal immediate release 2. History of intolerance to one of the following: a. generic lamotrigine 5
6 b. Lamictal immediate release 3. Patient is receiving lamotrigine extended-release for the treatment of a seizure disorder J. Lamotrigine Orally Disintegrating Tablet will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic lamotrigine (2) Lamictal immediate release b. History of an inadequate response to one of the following: (1) generic lamotrigine (2) Lamictal immediate release 2. History of intolerance to one of the following: a. generic lamotrigine b. Lamictal immediate release 3. Patient is receiving lamotrigine orally disintegrating tablet for the treatment of a seizure disorder K. Mysoline will be approved based on one of the following criteria: a. History of 2 week trial of primidone b. History of an inadequate response to primidone 6
7 2. History of intolerance to generic primidone formulations 3. Patient is receiving Mysoline for the treatment of a seizure disorder L. Neurontin will be approved based on one of the following criteria: a. History of 2 week trial of gabapentin -ANDb. History of an inadequate response to gabapentin 2. History of intolerance to generic gabapentin formulations 3. Patient is receiving Neurontin for the treatment of a seizure disorder M. Oxtellar XR* will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic oxcarbazepine (2) Trileptal b. History of an inadequate response to one of the following: (1) generic oxcarbazepine (2) Trileptal 2. History of intolerance to one of the following: 7
8 a. generic oxcarbazepine b. Trileptal 3. Patient is receiving Oxtellar XR for the treatment of a seizure disorder N. Spritam* will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic levetiracetam tablet (2) generic levetiracetam solution b. History of an inadequate response to one of the following: (1) generic levetiracetam tablet (2) generic levetiracetam solution 2. History of intolerance to one of the following: (1) generic levetiracetam tablet (2) generic levetiracetam solution 3. Patient is receiving Spritam for the treatment of a seizure disorder O. Trileptal will be approved based on one of the following criteria: a. History of 2 week trial of oxcarbazepine -ANDb. History of an inadequate response to oxcarbazepine 8
9 2. History of intolerance to generic oxcarbazepine formulations 3. Patient is receiving Trileptal for the treatment of a seizure disorder P. Topamax will be approved based on one of the following criteria: a. History of 2 week trial of topiramate -ANDb. History of an inadequate response to topiramate 2. History of intolerance to generic topiramate formulations 3. Patient is receiving Topamax for the treatment of a seizure disorder Q. Trokendi XR* or Qudexy XR* (brand and authorized generic) will be approved based on one of the following criteria: a. History of 2 week trial of one of the following: (1) generic topiramate (2) Topamax b. History of an inadequate response to one of the following: (1) generic topiramate (2) Topamax 9
10 2. History of intolerance to one of the following: (1) generic topiramate (2) Topamax 3. Patient is receiving Trokendi XR or Qudexy XR (brand and authorized generic) for the treatment of a seizure disorder R. Zonegran will be approved based on one of the following criteria: a. History of 2 week trial of zonisamide b. History of an inadequate response to zonisamide 2. History of intolerance to generic zonisamide formulations 3. Patient is receiving Zonegran for the treatment of a seizure disorder Authorization of therapy will be issued for 12 months. a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply. 3. Additional Clinical Rules: Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and reauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class. * Oxtellar XR, Qudexy XR (brand and authorized generic), Spritam and Trokendi XR are typically excluded from coverage. Please refer to plan specifics to determine exclusion status. 10
11 4. References: 1. Depakote Prescribing Information. AbbVie Inc. North Chicago, IL. October Depakote ER Prescribing Information. Abb Vie Inc. North Chicago, IL. October Keppra Prescribing Information. UCB; Smyrna, GA. October Keppra XR Prescribing Information. UCB; Smyrna, GA. October Lamictal and Lamictal ODT Prescribing Information. GSK; Research Triangle Park, NC. May Lamictal XR Prescribing Information. GSK; Research Triangle Park, NC. May Neurontin Prescribing Information. Pfizer, Inc. New York, NY. February Oxtellar XR Prescribing Information. Supernus Pharmaceuticals Inc. Rockville MD. December Qudexy XR Prescribing Information. Upsher-Smith Laboratories, Inc. Maple Grove, MN. March Topamax Prescribing Information. Janssen Ortho LLC; Titusville, NJ. June Trileptal Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ. March Trokendi XR Prescribing Information. Supernus Pharmaceuticals Inc. Rockville MD. January Zonegran Prescribing Information. Concordia Pharmaceuticals Inc. St. Michael, Barbados. April Felbatol Prescribing Information. Meda Pharmaceuticals Inc. Sommerset, NJ. July Mysoline Prescribing Information. Valeant Pharmaceuticals Inc. Bridgewater, NJ. January Spritam Prescribing Information. Aprecia Pharmaceuticals Company. East Windsor, NJ. February Program Step Therapy - Anticonvulsants Change Control Date Change 10/2013 Added lamotrigine orally disintegrating-tablet, and Trokendi XR as step 2 agents. Updated lamotrigine extended-release to include Lamictal XR as a step 1 agent. 11/2013 Added Depakote, Neurontin, Trileptal and Zonegran as step 2 agents. Updated Lamictal ODT and Lamictal XR to require the use of the corresponding generic before the brand is covered. 4/2014 Added lamotrigine as step one agent for Lamictal ODT tablets. Administrative changes. 7/2014 Added lamotrigine chewable tablet as step one agent for Lamictal ODT. 11/2014 Added levetiracetam as a step one agent for Keppra XR. 4/2015 Added Qudexy XR to criteria. Updated step one criteria for 11
12 Lamictal ODT to the generic product only. 1/2016 Added Felbatol and Mysoline to criteria. Added Maryland coverage information. 6/2016 Removed Stavzor from criteria as it has been discontinued. Added Spritam to criteria. Added Indiana and West Virginia coverage information. 11/2016 Administrative change. Added California coverage information. 6/2017 Annual review. Updated references. State mandate reference language updated. 9/2018 Annual review. Updated references. 12/2018 Administrative change to add statement regarding use of automated processes. 12
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2004-12 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2004-10 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol
Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lacosamide (Vimpat) Reference Number: CP.PMN.155 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2045-9 Program Prior Authorization/HCR- Tobacco Cessation - Health Care Reform Medication Bupropion SR (generic Zyban), Chantix
Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3086-5 Program Step Therapy Diabetes Medications - SGLT2 Inhibitors Medication Farxiga (dapagliflozin)*, Glyxambi (empagliflozin/linagliptan),
Self Report Seizure Survey Summary 2017
Self Report Seizure Survey Summary 2017 Tetrasomy 18p 61 responses 33 had at least one seizure = 54% 8 had a seizure in the last year Valproate (Depakote) 7 Valproate (Depakote, Epilium) 2 Lamotrigene
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Diacomit) Reference Number: CP.PMN.184 Effective Date: 09.25.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4005-2 Program Health Care Reform Tobacco Cessation Supply Limit (Therapy Duration) Override Kentucky Fully Insured Medication
Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
Page: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
Clinical Policy: Pregabalin (Lyrica) Reference Number: LA.PMN.33 Effective Date: Last Review Date: 07.18
Clinical Policy: (Lyrica) Reference Number: LA.PMN.33 Effective Date: 01.01.07 Last Review Date: 07.18 Line of Business:Medicaid Revision Log See Important Reminder at the end of this policy for important
UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
Methylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
Methylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
Non-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
Virtually every state in the United States REVIEW GENERIC AEDS: CURRENT STANDARDS AND RECOMMENDATIONS. Michel J. Berg, MD * ABSTRACT
GENERIC AEDS: CURRENT STANDARDS AND RECOMMENDATIONS Michel J. Berg, MD * ABSTRACT Among strong and conflicting viewpoints on the substitution of brand-name antiepileptic drugs (AEDs) with their generic
Clinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18
Clinical Policy: (Spritam) Reference Number: CP.CPA.156 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
Drug Use Research & Management Program Phone Fax Generic Bioequivalency Review of Antiepileptic Drugs and Immunosuppressants
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301 Phone 503-947-5220 Fax 503-947-1119 Generic Bioequivalency Review of Antiepileptic
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
Prescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
ADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
Anticonvulsant Prior Authorization Request
Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
Depakote for pain management
P ford residence southampton, ny Depakote for pain management Cancer patients often experience significant pain. Sometimes this is a side effect of the treatment, and sometimes because of the cancer itself.
OHSU Drug Effectiveness Review Project Summary Report Non-Opioid Drugs to Treat Neuropathic Pain
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017
Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA
A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
FORMULARY MANAGEMENT A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults NALIN PAYAKACHAT, MS; KENT H. SUMMERS, RPh, PhD; and JOHN P.
TRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2021-10 Program Prior Authorization/Medical Necessity Medication Xyrem (sodium oxybate) P&T Approval Date 4/2014, 8/2014, 4/2015,
1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 1/1/19, Cigna is making changes to our formularies that may impact medication coverage for customers at your pharmacy. We have included a
May 2017 P&T Updates
May 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives 6 ml per AMPYRA 3 2 2 tablets per day, 30 day BYDUREON 3 2 4 vials per 28 days 5 mcg pen: 1.2 ml per
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call To Order A meeting of the
Step Therapy Requirements. Effective: 03/01/2015
Effective: 03/01/2015 Updated 02/2015 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA OXTELLAR XR POTIGA QUDEXY
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1 ANTICONVULSANTS
Objectives / Learning Targets: The learner who successfully completes this lesson will be able to demonstrate understanding of the following concepts:
Boone County Fire District EMS Education-Paramedic Program EMS 270 Medical Cases-Seizures Resources Seizures screencast Seizures Flowchart and Seizures Flowchart Video Explanation Objectives / Learning
Opinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED
Commissioner for the Department for Medicaid Services Selections for Preferred Products
Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for
OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox- Gastaut syndrome
Journal of Market Access & Health Policy ISSN: (Print) 2001-6689 (Online) Journal homepage: https://www.tandfonline.com/loi/zjma20 Use and cost comparison of clobazam to other antiepileptic drugs for treatment
Medications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
Low dose depakote side effects
Low dose depakote side effects The Borg System is 100 % Low dose depakote side effects Oct 31, 2014. Studies also show if you take Depakote during pregnancy, your TEEN is at risk for having a lower IQ.
ANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION
Central Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
ANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection
Epilepsy Board Review Manual Statement of Editorial Purpose The Epilepsy Board Review Manual is a study guide for trainees and practicing physicians preparing for board examinations in epilepsy. Each manual
2017 United Healthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2055-10 Program Prior Authorization/Medical Necessity Medication Olysio (simeprevir) P&T Approval Date 4/2015, 11/2015, 8/2016,
SEIZURE PACKET. What is a seizure? What is epilepsy? Family Copy
What is a seizure? SEIZURE PACKET The brain sends electrical signals to all parts of the body. Each signal follows a special pathway. A seizure happens when the signals mix up. When signals get mixed up
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Absence seizures, 6 in childhood, 95 Adults, seizures and status epilepticus in, management of, 34 35 with first-time seizures. See Seizure(s),
QUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom
The brain sends electrical signals to all parts of the body. Each signal follows a special pathway. A seizure happens when the signals mix up.
What is a seizure? Seizure booklet The brain sends electrical signals to all parts of the body. Each signal follows a special pathway. A seizure happens when the signals mix up. 1. Signals mix up. They
Table A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents
Table A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents Food and Drug Administration. Guidance for Industry Adverse Reactions
FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19
1 FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19 Prescription Utilization Patterns and Hospitalizations in Epilepsy Patients on Anti Epileptic Drugs Abraham G. Hartzema,
FirstCarolinaCare Insurance Company. Step Therapy Requirements
FirstCarolinaCare Insurance Company Step Therapy Requirements Effective: 12/01/2018 ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION
Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E
Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET
Case 1: Issues in this case. Generalized Seizures. Seizure Rounds with S.Khoshbin M.D. Disclosures: NONE
Disclosures: NONE Seizure Rounds with S.Khoshbin M.D. Case 1: 45 yo male while jogging with his wife stopped,acted strangely for a while then fell to the ground and had a convulsion.emt s were called by
Alzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
Step Therapy Requirements
Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1078-11 Program Prior Authorization/Notification - Anticonvulsants Medication Aptiom (eslicarbazepine acetate); Banzel (rufinamide);
** Fee-For-Service Pharmacy Provider Notice #232 September 2018 PDL Changes **
** Fee-For-Service Pharmacy Provider Notice #232 September 2018 PDL Changes ** January 3, 2019 Please be advised that the Department for Medicaid Services (DMS) is making changes to the Kentucky Medicaid
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1078-10 Program Prior Authorization/Notification - Anticonvulsants Medication Aptiom (eslicarbazepine acetate); Banzel (rufinamide);
New AEDs in Pediatric Epilepsy
New AEDs in Pediatric Epilepsy John M. Pellock, MD Professor and Chairman Division of Child Neurology Children s Hospital of Richmond Virginia Commonwealth University Medical College of Virginia Hospitals
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
ANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA
What is a seizure? What is epilepsy?
What is a seizure? The brain sends electrical signals to all parts of the body. Each signal follows a special pathway. A seizure happens when the signals mix up. 1. Signals mix up. They do not meet or
Seizures and you. Michael B. Lloyd, MD
Seizures and you Michael B. Lloyd, MD Objectives Definition Epidemiology Classification Epileptic syndromes Differential and recognition Work-up Treatment Frequently asked questions Definition Sudden
ANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
New Patient Questionnaire - Epilepsy
New Patient Questionnaire - Epilepsy Person completing this form: (if other than the patient) GENERAL SEIZURE HISTORY Relationship: When do you think your child had their first seizure? When was the last
Understanding and Managing Epilepsy
Page 1 Understanding and Managing Epilepsy Jacquelyn L. Bainbridge, Pharm.D., FCCP Associate Professor University of Colorado Denver School of Pharmacy & Department of Neurology Supported by an educational
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
ANTIEPILEPTIC Medicines
ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become
AAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
Epilepsy. Annual Incidence. Adult Epilepsy Update
Adult Epilepsy Update Annual Incidence J. Layne Moore, MD, MPH Associate Professor Department of Neurology and Pharmacy Director, Division of Epilepsy The Ohio State University Used by permission Health
Discerning Seizures and Understanding VNS Therapy Delia Nickolaus, CPNP-PC/AC
O U T R E A C H E D U C A T I O N Discerning and Understanding VNS Therapy Delia Nickolaus, CPNP-PC/AC Program Handouts This information is provided as a courtesy by Children's Health Care System and its
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
2017 Step Therapy Criteria
FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.
Pharmacy Medical Necessity Guidelines: Migraine Medications
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
In clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.17 Subject: Gabapentin Page: 1 of 6 Last Review Date: June 22, 2017 Gabapentin Description Gabapentin
Investor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2099-5 Program Prior Authorization/Medical Necessity Buprenorphine Products (Pain Indications) Medication Belbuca (buprenorphine
Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this